Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM1305
- Development stage
- Preclinical
- Lead developer
- Purple Biotech
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IM1305 is a conditionally activated trispecific antibody developed by Purple Biotech using the CAPTN-3 platform. It is designed to target the tumor-associated antigen TROP2, which is widely expressed in solid tumors such as breast, lung, and gastrointestinal cancers. The antibody features a unique masked or capped CD3-binding arm that is specifically activated within the tumor microenvironment via a cleavable linker, thereby reducing systemic off-target effects. Additionally, IM1305 incorporates an anti-NKG2A arm to engage and modulate natural killer (NK) cell activity alongside T-cell recruitment. Preclinical studies have demonstrated potent tumor regression in humanized mouse models of triple-negative breast cancer (TNBC).
- Other names
- capped-CD3xTROP2xNKG2A trispecific antibodycapped-CD-3xTROP2xNKG2A trispecific antibodycapped-CD 3xTROP2xNKG2A trispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)KLRC1 (Killer cell lectin-like receptor subfamily C member 1)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on IM1305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM1305.